|
🐜
|
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia.
25 auth.
S. O’Brien,
F. Guilhot,
R. Larson,
I. Gathmann,
M. Baccarani,
F. Cervantes,
J. Cornelissen,
T. Fischer,
A. Hochhaus,
T. Hughes,
K. Lechner,
J. L. Nielsen,
P. Rousselot,
J. Reiffers,
G. Saglio,
...
J. Shepherd,
B. Simonsson,
A. Gratwohl,
J. Goldman,
H. Kantarjian,
K. Taylor,
G. Verhoef,
A. Bolton,
R. Capdeville,
B. Druker
|
11 |
2003 |
11
🐜
|
|
🐜
|
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
32 auth.
B. Druker,
F. Guilhot,
S. O’Brien,
I. Gathmann,
H. Kantarjian,
N. Gattermann,
M. Deininger,
R. Silver,
J. Goldman,
R. Stone,
F. Cervantes,
A. Hochhaus,
B. Powell,
J. Gabrilove,
P. Rousselot,
...
J. Reiffers,
J. Cornelissen,
T. Hughes,
H. Agis,
T. Fischer,
G. Verhoef,
J. Shepherd,
G. Saglio,
A. Gratwohl,
J. L. Nielsen,
J. Radich,
B. Simonsson,
K. Taylor,
M. Baccarani,
Charlene So,
L. Letvak,
R. Larson
|
11 |
2006 |
11
🐜
|
|
🐜
|
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
32 auth.
M. Baccarani,
M. Deininger,
G. Rosti,
A. Hochhaus,
S. Soverini,
J. Apperley,
F. Cervantes,
R. Clark,
J. Cortes,
F. Guilhot,
H. Hjorth-Hansen,
T. Hughes,
H. Kantarjian,
Dong-Wook Kim,
R. Larson,
...
J. Lipton,
F. Mahon,
G. Martinelli,
J. Mayer,
Martin C. Müller,
D. Niederwieser,
F. Pane,
J. Radich,
P. Rousselot,
G. Saglio,
S. Saussele,
C. Schiffer,
R. Silver,
B. Simonsson,
J. Steegmann,
J. Goldman,
R. Hehlmann
|
10 |
2013 |
10
🐜
|
|
🐜
|
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
14 auth.
C. Harrison,
J. Kiladjian,
H. Al-Ali,
H. Gisslinger,
R. Waltzman,
V. Stalbovskaya,
M. Mcquitty,
D. Hunter,
R. Levy,
L. Knoops,
...
F. Cervantes,
A. Vannucchi,
T. Barbui,
G. Barosi
|
10 |
2012 |
10
🐜
|
|
🐜
|
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
19 auth.
M. Baccarani,
G. Saglio,
J. Goldman,
A. Hochhaus,
B. Simonsson,
F. Appelbaum,
J. Apperley,
F. Cervantes,
J. Cortes,
M. Deininger,
...
A. Gratwohl,
F. Guilhot,
M. Horowitz,
T. Hughes,
H. Kantarjian,
R. Larson,
D. Niederwieser,
R. Silver,
R. Hehlmann
|
10 |
2006 |
10
🐜
|
|
🐜
|
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
20 auth.
M. Baccarani,
J. Cortes,
F. Pane,
D. Niederwieser,
G. Saglio,
J. Apperley,
F. Cervantes,
M. Deininger,
A. Gratwohl,
F. Guilhot,
...
A. Hochhaus,
M. Horowitz,
T. Hughes,
H. Kantarjian,
R. Larson,
J. Radich,
B. Simonsson,
R. Silver,
J. Goldman,
R. Hehlmann
|
10 |
2009 |
10
🐜
|
|
🦁
|
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
12 auth.
F. Cervantes,
B. Dupriez,
Arturo Pereira,
F. Passamonti,
J. Reilly,
E. Morra,
...
A. Vannucchi,
R. Mesa,
J. Demory,
G. Barosi,
E. Rumi,
A. Tefferi
|
10 |
2008 |
10
🦁
|
|
🐜
|
Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
18 auth.
T. Ernst,
A. Chase,
J. Score,
Claire E Hidalgo-Curtis,
C. Bryant,
A. Jones,
K. Waghorn,
K. Zoi,
F. Ross,
A. Reiter,
...
A. Hochhaus,
H. Drexler,
A. Duncombe,
F. Cervantes,
D. Oscier,
J. Boultwood,
F. Grand,
N. Cross
|
10 |
2010 |
10
🐜
|
|
🐜
|
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
34 auth.
A. Hochhaus,
M. Baccarani,
R. Silver,
C. Schiffer,
J. Apperley,
F. Cervantes,
R. Clark,
J. Cortes,
M. Deininger,
F. Guilhot,
H. Hjorth-Hansen,
T. Hughes,
J. Janssen,
H. Kantarjian,
Dong-Kee Kim,
...
R. Larson,
J. Lipton,
F. Mahon,
J. Mayer,
F. Nicolini,
D. Niederwieser,
F. Pane,
J. Radich,
D. Réa,
J. Richter,
G. Rosti,
P. Rousselot,
G. Saglio,
Susanne Saussele,
S. Soverini,
J. Steegmann,
A. Turkina,
A. Zaritskey,
Ruediger Hehlmann
|
10 |
2020 |
10
🐜
|
|
🐜
|
Long‐Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia
15 auth.
A. Hochhaus,
R. Larson,
F. Guilhot,
J. Radich,
S. Branford,
T. Hughes,
M. Baccarani,
M. Deininger,
F. Cervantes,
Satoko Fujihara,
...
C. Ortmann,
H. Menssen,
H. Kantarjian,
S. O’Brien,
B. Druker
|
9 |
2017 |
9
🐜
|
|
🐜
|
DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status.
13 auth.
N. Gangat,
D. Caramazza,
R. Vaidya,
G. George,
K. Begna,
S. Schwager,
D. V. Van Dyke,
C. Hanson,
Wenting Wu,
A. Pardanani,
...
F. Cervantes,
F. Passamonti,
A. Tefferi
|
9 |
2011 |
9
🐜
|
|
🐜
|
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel.
19 auth.
A. Tefferi,
J. Thiele,
A. Orazi,
H. Kvasnicka,
T. Barbui,
C. Hanson,
G. Barosi,
S. Verstovsek,
G. Birgegard,
R. Mesa,
...
J. Reilly,
H. Gisslinger,
A. Vannucchi,
F. Cervantes,
G. Finazzi,
R. Hoffman,
D. Gilliland,
C. Bloomfield,
J. Vardiman
|
9 |
2007 |
9
🐜
|
|
🐜
|
A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).
14 auth.
F. Passamonti,
F. Cervantes,
A. Vannucchi,
E. Morra,
E. Rumi,
Arturo Pereira,
P. Guglielmelli,
E. Pungolino,
M. Caramella,
M. Maffioli,
...
C. Pascutto,
M. Lazzarino,
M. Cazzola,
A. Tefferi
|
9 |
2010 |
9
🐜
|
|
🐜
|
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet.
21 auth.
T. Barbui,
G. Barosi,
G. Birgegard,
F. Cervantes,
G. Finazzi,
M. Griesshammer,
C. Harrison,
H. Hasselbalch,
R. Hehlmann,
R. Hoffman,
...
J. Kiladjian,
N. Kröger,
R. Mesa,
M. McMullin,
A. Pardanani,
F. Passamonti,
A. Vannucchi,
A. Reiter,
R. Silver,
S. Verstovsek,
A. Tefferi
|
9 |
2011 |
9
🐜
|
